SCHEMBL129820

SCHEMBL129820

Cc1cccc(-c2nn(C)c3ncnc(N)c23)c1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 13/20 0.76
PIK3CA P42336 13/20 0.76
PIK3CB P42338 13/20 0.76
PIK3CG P48736 13/20 0.76
PRKDC P78527 13/20 0.76
SRC P12931 14/20 0.71
ABL1 P00519 12/20 0.71
EGFR P00533 10/20 0.67
HCK P08631 10/20 0.67
MTOR P42345 10/20 0.67
EPHB4 P54760 10/20 0.67
KDR P35968 9/20 0.67
PI4KB Q9UBF8 3/20 0.65
AURKA O14965 1/20 0.64
IKBKE Q14164 1/20 0.64
AURKB Q96GD4 1/20 0.64
NUDT14 O95848 1/20 0.58
NUDT5 Q9UKK9 1/20 0.58
RIPK1 Q13546 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL130421 0.88 PIK3CD (0.78) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL130589 0.85 PIK3CG (0.74) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL12351 0.85 PIK3CD (0.74) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL409367 0.84 PIK3CD (0.82) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL14574629 0.83 SRC (0.98) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL29390907 0.83 SRC (0.98) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL409486 0.83 SRC (1.00) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL128499 0.83 PIK3CD (0.71) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL130590 0.83 SRC (0.73) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL13826003 0.83 SRC (0.68) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 US disclosed
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2015-11-12 US disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB PIK3CD 47/4885PIK3CA 88/4885PIK3CB 23/4885
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB PIK3CD 47/4885PIK3CA 88/4885PIK3CB 23/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB PIK3CD 47/4885PIK3CA 88/4885PIK3CB 23/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A PIK3CD 103/4885PIK3CA 144/4885PIK3CB 102/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.